The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.00
Ask: 65.00
Change: 0.50 (0.79%)
Spread: 2.00 (3.175%)
Open: 63.50
High: 64.00
Low: 63.50
Prev. Close: 63.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 Jun 2015 07:00

RNS Number : 3111P
MyCelx Technologies Corporation
05 June 2015
 



5 June 2015

 

MyCelx Technologies Corporation

("MyCelx" or the "Company" (AIM: MYX))

 

Dealing by Directors

 

The Company announces that on 3 June 2015, Tim Eggar, Chairman and a Director of the Company, notified the Company that he had exercised options over 50,459 common shares of US$0.025 each ("Common Shares") under the Company's Omnibus Performance Incentive Plan 2011 (the "Plan") at a price of US$0.86 per Common Share.

 

Following this transaction, Mr Eggar now holds 130,679 Common Shares, representing 0.70 per cent of the increased issued capital of the Company.

 

The Company further announces that on 3 June 2015, Brian Rochester, a Director of the Company, notified the Company that he had exercised options over 41,143 Common Shares under the Plan at a price of US$0.86 per Common Share.

 

Following this transaction, Mr Rochester now holds 41,143 Common Shares, representing 0.22 per cent of the increased issued capital of the Company. R. Bros. Investments LLC, in which Mr Rochester holds a 50% interest, also holds 191,305 Common Shares representing 1.02 per cent of the increased issued capital of the Company. Mrs Alana Rochester, Mr Rochester's wife, also holds 32,044 Common Shares, representing 0.17 per cent of the increased issued capital of the Company.

 

Exercise of Share Option by Significant Shareholder

 

The Company further announces that on 3 June 2015, John Mansfield Sr., Chairman Emeritus and co-founder of the Company and a former Director of the Company, notified the Company that he had exercised an option over 54,340 Common Shares under the Plan at a price of US$0.86 per Common Share. In accordance with the provisions of the Plan, the subscription price for 32,296 Common Shares forming part of this option was settled by the cancellation of the balance of 22,044 Common Shares, based on the market value of the Common Shares at the time of exercise.

 

Following this transaction, Mr Mansfield now holds 1,703,380 Common shares, representing 9.07 per cent of the increased issued capital of the Company. This aggregate number of shares includes a holding by Mansfield Holdings LLC, a limited liability company controlled by Mr Mansfield, of 205,082 Common Shares representing 1.09 per cent of the increased issued capital of the Company.

 

Exercise of Share Option

 

The Company further announces that on 3 June 2015, an option over 24,065 Common Shares under the Plan was exercised by a former director at a price of US$0.86 per Common Share. In accordance with the provisions of the Plan, the subscription price for 14,439 Common Shares forming part of this option was settled by the cancellation of the balance of 9,626 Common Shares, based on the market value of the Common Shares at the time of exercise, and 14,439 Common Shares have been allotted.

 

Block Admission

 

A total of 138,337 new Common Shares have been allotted under the Company's Block Admission of 300,000 Common Shares admitted to AIM on 29 April 2013.

 

Total Voting Rights

 

Following the issue of 138,337 new Common Shares referred to above, the total number of voting rights in the Company's Common Shares is 18,770,117 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, MyCelx under the Financial Conduct Authority's Disclosure and Transparency Rules. The Company does not hold any Common Shares in treasury.

 

 

For further information please contact:

 

MyCelx Technologies Corporation

Connie Mixon, CEO

Mark Clark, CFO

Tel: +1 888 306 6843

 

Numis Securities Limited

Corporate Finance

John Prior

Paul Gillam

 

Corporate Broking

James Black

Ben Stoop

Tel: +44 20 7260 1000

 

Bell Pottinger

Nick Lambert

Henry Lerwill

Tel: +44 20 3772 2500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLFFFIRLISIIE
Date   Source Headline
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company
14th Oct 20217:00 amRNSMiddle East Contract Win
29th Sep 20217:00 amRNSHalf Year Results Statement
31st Aug 20217:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20217:00 amRNSHolding(s) in Company
4th Aug 20217:00 amRNSContract Award and Contract Extension
7th Jul 20215:41 pmRNSResult of AGM
4th Jun 20218:00 amRNSMailing of Annual Financial Report and AM Notice
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.